GEHC
stock Healthcare Medical DevicesOverall Mixed · 50%
- Fundamentals Fair
- Trajectory Steady
- Leadership Normal
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bearish 0 of 5 trend signals bullishRSI 41 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $62.03
- +0.06%
- Close
- $62.03
- +0.06%
- Current
- $62.03
- Prev close
- $61.99
- Today
- 3.92M
- 3-mo avg
- 4.72M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2983 days ago
- Next expected
- Jul 29in 8 days
Recent earnings dates
- Apr 29 83 days ago
- Feb 4 167 days ago
- Oct 29, 2025 265 days ago
- Jul 30, 2025 356 days ago
Past earnings dates come from GEHC’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), GEHC’s fundamentals read as fair overall.
At 14.9x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 0.2% yield is modest: a small income on top of whatever the share price does.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 10.1% margin is solid, in the ordinary range for a profitable company.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 20.1% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 5.6% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 2.53, the company leans heavily on borrowing, which adds risk if results weaken.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.37, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 4.8% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 4.6% from the prior year: steady profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B |
| Net income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B |
| Diluted EPS | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 |
| Dividend / share | — | — | $0.12 | $0.12 | $0.14 |
| Total assets | — | $27.5B | $32.5B | $33.1B | $36.9B |
| Total liabilities | — | $17.9B | $25.1B | $24.4B | $26.3B |
| Shareholder equity | $16.7B | $9.4B | $7.1B | $8.4B | $10.4B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8B | $4.9B | $5.3B | $4.8B | $5.0B | $5.1B | $5.7B | $5.1B |
| Net income | $428.0M | $470.0M | $721.0M | $564.0M | $486.0M | $446.0M | $588.0M | $389.0M |
| Diluted EPS | $0.93 | $1.02 | $1.58 | $1.23 | $1.06 | $0.98 | $1.28 | $0.85 |
| Dividend / share | $0.03 | $0.03 | $0.04 | $0.04 | — | $0.07 | — | $0.04 |
Leadershipsynced from SEC 56d ago
- Bankes Jeannette CEO, Patient Care Solutions
- Rackliffe Philip CEO, AIS
- Culp H Lawrence Jr Director
- Hochman Rodney F Director
- Lesjak Catherine A Director
- Lobo Kevin Director
- Madden Anne T Director
- Stromberg William J Director
- Yang Watkin Phoebe L. Director
Officers and board are drawn from GEHC’s recent SEC ownership filings (Forms 3, 4 and 5).
Recent leadership changes
Notable recent eventspast year
- Apr 29 −13.2% one-day move
- Apr 28 New 6-month low (-22% off peak)
- Apr 8 +5.8% one-day move
- Mar 17 Officer or director change reported in an 8-K
- Mar 12 New 6-month low (-20% off peak)
- Jul 30, 2025 −7.8% one-day move
- Jul 24, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 52d ago
- 2025 total
- $0.14
- 2026 so far
- $0.072 payments
- 2026 projected
- $0.14+0.0% vs 2025
Projection scales GEHC’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- Apr 2 $0.04
- Jan 9 $0.04
- Oct 24, 2025 $0.04
- Jul 25, 2025 $0.04
- Apr 25, 2025 $0.04
- Jan 14, 2025 $0.04
- Oct 18, 2024 $0.03
- Jul 19, 2024 $0.03
- Apr 18, 2024 $0.03
- Jan 12, 2024 $0.03
- Oct 19, 2023 $0.03
- Jul 20, 2023 $0.03
- May 22, 2023 $0.03
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report